Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Jun. 30, 2017 | Aug. 17, 2017 | |
Document Type | 10-Q | |
Amendment Flag | false | |
Document Period End Date | Jun. 30, 2017 | |
Trading Symbol | odt | |
Entity Registrant Name | ONLINE DISRUPTIVE TECHNOLOGIES, INC. | |
Entity Central Index Key | 1,498,380 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 118,013,408 | |
Entity Current Reporting Status | Yes | |
Entity Voluntary Filers | No | |
Entity Well Known Seasoned Issuer | No | |
Document Fiscal Year Focus | 2,017 | |
Document Fiscal Period Focus | Q2 |
Condensed Interim Consolidated
Condensed Interim Consolidated Balance Sheets - USD ($) | Jun. 30, 2017 | Dec. 31, 2016 |
Current Assets | ||
Cash and Cash Equivalents | $ 242,053 | $ 452,376 |
Prepaid expenses | 1,859 | 1,687 |
VAT Receivable | 11,668 | 28,907 |
Total Current Assets | 255,580 | 482,970 |
Restricted cash | 22,980 | 20,857 |
Fixed Assets | 53,828 | 55,444 |
Total Assets | 332,388 | 559,271 |
Current Liabilities | ||
Accounts Payable | 278,370 | 61,356 |
Accrued Liabilities | 127,966 | 115,650 |
Total Current Liabilities | 406,336 | 177,006 |
Convertible debentures | 869,657 | 729,475 |
Total Liabilities | 1,275,993 | 906,481 |
(DEFICIT)/EQUITY | ||
Authorized: 20,000,000 Preferred Shares, par value $0.001 500,000,000 Common Shares, par value $0.001 Issued and outstanding: Nil Preferred Shares 117,413,408 Common Shares (December 31, 2016: 114,180,828 Common Shares) | 101,814 | 98,581 |
Additional Paid-in Capital | 10,047,083 | 9,409,875 |
Share Subscription Received | 0 | 158,750 |
Accumulated Other Comprehensive Loss | (107,126) | (88,180) |
Deficit | (10,951,279) | (9,982,269) |
(Deficit)/Equity Attributable to Shareholders of the Company | (909,508) | (403,243) |
Non-Controlling Interests | (34,097) | 56,033 |
Total (Deficit)/Equity | (943,605) | (347,210) |
Total Liabilities and (Deficit)/Equity | $ 332,388 | $ 559,271 |
Condensed Interim Consolidated3
Condensed Interim Consolidated Balance Sheets (Parenthetical) - $ / shares | Jun. 30, 2017 | Dec. 31, 2016 |
Preferred Stock, Shares Authorized | 20,000,000 | 20,000,000 |
Preferred Stock, Par Value Per Share | $ 0.001 | $ 0.001 |
Common Stock, Shares Authorized | 500,000,000 | 500,000,000 |
Common Stock, Par Value Per Share | $ 0.001 | $ 0.001 |
Common Stock, Shares, Issued | 117,413,408 | 114,180,828 |
Common Stock, Shares, Outstanding | 117,413,408 | 114,180,828 |
Consolidated Statements of Oper
Consolidated Statements of Operations and Comprehensive Loss - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2017 | Jun. 30, 2016 | Jun. 30, 2017 | Jun. 30, 2016 | |
General and Administrative Expenses | ||||
Accounting Fees | $ 7,500 | $ 7,500 | $ 15,000 | $ 15,000 |
Audit & Tax Fees | 9,997 | 10,159 | 43,979 | 54,560 |
Bank Fees | 112 | 114 | 375 | 242 |
Consulting Fees | 95,011 | 91,972 | 186,663 | 183,944 |
Filing and Transfer Agent Fees | 3,203 | 7,146 | 5,476 | 7,729 |
Legal Fees | 7,679 | 15,563 | 18,811 | 25,002 |
Travel Expenses | 2,868 | 3,263 | 4,998 | 6,694 |
Office and Miscellaneous Expense | 13,631 | 5,530 | 21,981 | 31,275 |
Research and Development Expense | 365,899 | 398,410 | 609,880 | 673,882 |
Marketing Expense | 2,731 | 0 | 2,731 | 0 |
Payroll Expense | 9,031 | 8,566 | 17,733 | 16,885 |
Rent Expense | 954 | 1,469 | 2,171 | 2,692 |
Insurance Expense | 13,575 | 29,825 | 22,742 | 41,588 |
Total General and Administrative Expenses | (532,191) | (579,517) | (952,540) | (1,059,493) |
Other Expense | ||||
Interest Accretion | (76,084) | (39,731) | (140,182) | (73,519) |
Interest Expense | (69) | (63) | (124) | (128) |
Foreign Currency Gain (Loss) | 23,170 | (10,264) | 36,449 | (5,886) |
Net (Loss) for the period | (585,174) | (629,575) | (1,056,397) | (1,139,026) |
Other Comprehensive Income | ||||
Currency translation adjustments | (4,398) | (15,478) | (18,946) | (3,927) |
Comprehensive (Loss) for the period | (589,572) | (645,053) | (1,075,343) | (1,142,953) |
Net (Loss) attributable to: | ||||
Common Stockholders | (521,217) | (545,331) | (969,011) | (986,795) |
Non-Controlling Interests | (49,409) | (84,244) | (87,386) | (152,231) |
Net loss for the year | (585,174) | (629,575) | (1,056,397) | (1,139,026) |
Net Comprehensive (Loss) Attributable to: | ||||
Common Stockholders | (537,688) | (558,741) | (986,390) | (990,196) |
Non-Controlling Interests | (51,884) | (86,312) | (88,953) | (152,757) |
Comprehensive Income (Loss) for the period | $ (589,572) | $ (645,053) | $ (1,075,343) | $ (1,142,953) |
Basic and Diluted Net Loss per Common Share | $ 0 | $ (0.01) | $ (0.01) | $ (0.01) |
Weighted Average Number of Common Shares Outstanding - Basic and Diluted | 116,601,707 | 106,207,916 | 115,397,955 | 103,559,255 |
Condensed Interim Consolidated5
Condensed Interim Consolidated Statements of Cash Flows - USD ($) | 6 Months Ended | |
Jun. 30, 2017 | Jun. 30, 2016 | |
Cash flow from Operating Activities | ||
Net loss for the year | $ (1,056,397) | $ (1,139,026) |
Adjustment for items not involving cash: | ||
Stock-Based Compensation | 89,392 | 150,406 |
Foreign exchange gain/loss | (36,449) | 5,886 |
Depreciation - fixed assets | 6,918 | 0 |
Interest accretion | 140,182 | 73,519 |
Changes in non-cash working capital items: | ||
Decrease(increase) in VAT receivable | 19,228 | (6,910) |
(Decrease) in prepaid expense | 0 | 1,003 |
Increase (decrease) in accounts payable and accrued liabilities | 216,400 | 107,614 |
Net cash (used in) operating activities | (620,726) | (807,508) |
Cash flow from financing activities | ||
Share subscription received | 413,500 | 625,000 |
Net cash provided by financing activities | 413,500 | 625,000 |
Cash flow from investing activities | ||
Cash utilized in purchase of assets | 0 | (7,198) |
Net cash provided by (used in) investing activities | 0 | (7,198) |
Effects of exchange rate changes on cash and cash equivalents | (3,097) | (9,435) |
Net decrease in cash and cash equivalents | (210,323) | (199,141) |
Cash and cash equivalents, beginning of period | 452,376 | 1,206,809 |
Cash and cash equivalents, end of period | 242,053 | 1,007,668 |
Supplementary Information | ||
Interest Paid | 0 | 0 |
Income Taxes Paid | $ 0 | $ 0 |
Nature of Operations and going
Nature of Operations and going concern | 6 Months Ended |
Jun. 30, 2017 | |
Nature of Operations and going concern [Text Block] | Note 1 - Nature of Operations and going concern Online Disruptive Technologies, Inc. (“ODT” or the “Company”) was incorporated on November 16, 2009 in the State of Nevada, U.S.A. The Company was in the business of operating websites with advertising revenue platforms. However, as described below, the Company changed its primary business focus to the development and commercialization of a biotechnology platform. The Company has limited operations that has had no revenues from inception to date. The Company has a December 31 year-end. Effective March 24, 2010, the Company acquired 100% of the issued and outstanding shares of RelationshipScoreboard.com Entertainment Inc. (“RS” or “RelationshipScoreboard.com”), a company incorporated on November 16, 2009 in the state of Nevada, U.S.A. in exchange for 16,000,000 shares of the Company’s common stock. Upon the completion of the acquisition, the former sole shareholder of RS held 89% of the Company’s issued and outstanding common stock. As a result, the transaction was accounted for as a reverse takeover transaction (“RTO”) for accounting purpose, as RS was deemed to be the acquirer, and these Condensed Interim Consolidated Financial Statements are a continuation of the financial statements of RS. On January 28, 2013, RelationshipScoreboard.com was closed and dissolved. The Company sold the website assets for $10 to an arm’s length individual and wrote off all supplier payables in the amount of $430. On April 23, 2012, the Company established an Israeli subsidiary named Savicell Diagnostic Ltd. (“Savicell”) with the intention of exploring business ventures in the biotechnology sector. On July 25, 2012, Savicell entered into a definitive licensing agreement with a division of the Tel Aviv University for the purpose of developing and commercializing a new technology relative to the early detection of various forms of disease. With the consummation of this transaction, the Company is now entirely focused on its biotechnology efforts. These Condensed Interim Consolidated Financial Statements have been prepared with the ongoing assumption that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. The Company has a negative working capital balance of $150,756 as at June 30, 2017 (December 31, 2016 – $305,964) and an accumulated deficit of $10,951,279 (December 31, 2016 – $9,982,269). Furthermore, additional future losses are anticipated which raise substantial doubt about the Company’s ability to continue as a going concern. These Condensed Interim Consolidated Financial Statements do not include any adjustments to the amounts and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. The operations of the Company have primarily been funded by the sale of common shares and loans received. Continued operations of the Company are dependent on the Company’s ability to complete equity financings or to generate profitable operations in the future. Management’s plan in this regard is to secure additional funds through future equity financings. Such financings may not be available or may not be available on reasonable terms to the Company. Failure to obtain the ongoing support of its equity financings and creditors may make the going concern basis of accounting inappropriate, in which case the Company’s assets and liabilities would need to be recognized at their liquidation values. These consolidation financial statements do not include any adjustments relating to the recoverability and classification of recorded assets amounts and classification of liabilities that might arise from this uncertainty. |
Significant Accounting Policies
Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2017 | |
Significant Accounting Policies [Text Block] | Note 2 - Significant Accounting Policies a) Basis of Presentation b) Principles of Consolidation c) Use of Estimates Significant areas requiring the use of management estimates include assumptions and estimates relating to share-based payments, valuation allowances for deferred income tax assets and determination of useful lives of property, plant and equipment. d) Foreign Currency Translation The Company’s subsidiary’s functional currency is the New Israeli Shekel (“NIS”). All transactions are recorded in NIS. Monetary assets and liabilities denominated in NIS are translated into U.S. dollars at rates of exchange in effect at the balance sheet dates and expenses are translated at the average exchange rates. Gains and losses from such translations are included in stockholders’ equity, as a component of other comprehensive income. In the year ended 2013, Savicell’s functional currency was the U.S. dollar. During the year 2014, with the increased volume of transactions in the local currency, the management reassessed Savicell’s functional currency to NIS based on the change in facts and effective as of January 1, 2014. Such change is still appropriate in 2016. As a result of the functional currency change discussed above, a cumulative translation adjustment of $18,946 is included in accumulated other comprehensive income and will only be adjusted in the event of a full or partial disposition of the Company's investment in Savicell. e) Cash and Cash Equivalents f) Stock-based Compensation Share-based payments issued to non-employees are recorded at their fair values at each reporting date, as the equity instruments vest and are recognized as expense over the related service period in accordance with the provisions of ASC 718 and ASC Topic 505, Equity. For equity instruments granted to non-employees, the Company recognizes stock-based compensation expense on a straight-line basis. g) Income Taxes Per FASB ASC 740 “Income taxes” under the liability method, it is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. At June 30, 2017, the Company believes it has appropriately accounted for any unrecognized tax benefits. To the extent the Company prevails in matters for which a liability for an unrecognized benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected. Interest and penalties associated with the Company’s tax positions are recorded as Interest Expense. h) Comprehensive Income (Loss) i) Earnings (Loss) Per Share Diluted loss per share is computed on the basis of the weighted average number of common shares and dilutive securities outstanding. Stock options are considered to be common stock equivalents and were not included in the net loss per share calculation for the six months ended June 30, 2017 and 2016 because the inclusion of such underlying shares would have had an anti-dilutive effect. j) Financial Instruments and Fair Value of Financial Instruments - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. As at June 30, 2017, the fair value of cash and cash equivalents was measured using Level 1 inputs. The Company’s financial instruments are cash and cash equivalents, restricted cash, VAT receivables, accounts payable and accrued liabilities and convertible debentures. The recorded values of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The Company believes the recorded values of convertible debentures, net of the discount, approximate the fair value as the interest rate (stated or effective) approximates market rates for similar types of instruments. k) Research and Development Costs Three Months Ended Three Months Ended Six Months Ended Six Months Ended June 30, 2017 June 30, 2016 June 30, 2017 June 30, 2016 Research and Development $ $ $ $ Expenses Consulting fees 33,372 56,103 58,190 70,795 Legal fees 15,621 8,138 22,330 8,138 Office and Miscellaneous Expense 6,135 - 9,936 6,314 Payroll expense 236,279 181,166 361,114 331,632 R&D materials and supplies 11,387 68,417 42,604 88,684 Rent 8,579 6,907 19,535 17,912 Share-based compensation 47,747 77,679 89,392 150,406 6,779 Insurance - 6,779 - Total 365,899 398,410 609,880 673,881 Savicell’s financing commitment related to the License and Research Funding Agreement (as defined in Note 4 below) entered into with Ramot at Tel Aviv University was completely fulfilled by December 31, 2015. l) Fixed Assets Class of Properties Amortization Rate Furniture and Fixtures 15 -year; straight-line basis Computer Equipment 3 to 4 -year; straight-line basis Lab Equipment 3 to 15 -year; straight-line basis m) Convertible debentures n) Modifications to debt o) Recently Adopted Accounting Pronouncements p) Recently Issued Accounting Pronouncements On November 17, 2016, the FASB issued ASU 2016-18, Restricted Cash. Entities will be required to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated financial statements, if any. In March 2016, the FASB issued ASU 2016-02, Leases, which supersedes ASC Topic 840, Leases, and sets forth the principles for the recognition, measurement, presentation, and disclosure of leases for both lessees and lessors. ASU 2016-02 requires lessees to classify leases as either finance or operating leases and to record on the balance sheet a right-of-use asset and a lease liability, equal to the present value of the remaining lease payments, for all leases with a term greater than 12 months regardless of the lease classification. The lease classification will determine whether the lease expense is recognized based on an effective interest rate method or a straight-line basis over the term of the lease. ASU 2016-02 will be effective for us beginning January 1, 2019, with early adoption permitted. Entities are required to use a modified retrospective transition method for existing leases. We are currently evaluating the potential impact this guidance will have on our consolidated financial statements. In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The amendments to the guidance enhance the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation, and disclosure. The updated guidance is effective for us beginning January 1, 2018. We do not expect this guidance to have a material impact on our consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, as a new Topic, ASC 606. The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Companies may apply the new guidance using either the full retrospective transition method, which requires restating each prior period presented, or the modified retrospective transition method, under which the new guidance is applied to the current period presented in the financial statements and a cumulative-effect adjustment is recorded as of the date of adoption. We are currently evaluating the potential impact this guidance will have on our consolidated financial statements. |
Fixed Assets
Fixed Assets | 6 Months Ended |
Jun. 30, 2017 | |
Fixed Assets [Text Block] | Note 3 – Fixed Assets As of June 30, 2017, the fixed assets balance on the financial statement consist of the following: Furniture and Computer Cost: Fixtures Equipment Lab Equipment Total December 31, 2016 $ 3,496 $ 26,489 $ 44,432 $ 74,417 Exchange difference 357 2,697 4,523 7,577 June 30, 2017 $ 3,853 $ 29,186 $ 48,955 $ 81,994 Furniture and Computer Amortization: Fixtures Equipment Lab Equipment Total December 31, 2016 $ 404 $ 10,645 $ 7,924 $ 18,973 Additions 207 3,818 2,890 6,915 Exchange difference 52 1,276 950 2,278 June 30, 2017 $ 663 $ 15,739 $ 11,764 $ 28,166 Furniture and Computer Net Book Value: Fixtures Equipment Lab Equipment Total December 31, 2016 $ 3,092 $ 15,844 $ 36,508 $ 55,444 June 30, 2017 $ 3,190 $ 13,447 $ 37,191 $ 53,828 |
License and Research Funding Ag
License and Research Funding Agreement | 6 Months Ended |
Jun. 30, 2017 | |
License and Research Funding Agreement [Text Block] | Note 4 – License and Research Funding Agreement On July 25, 2012, the Company’s subsidiary Savicell entered into a License and Research Funding Agreement (“R&D Agreement”) with Ramot at Tel Aviv University (“Ramot”) pursuant to which: In the course of research performed at Tel-Aviv University (" TAU Savicell wishes to fund further research at TAU relating to such technology; and Savicell wishes to obtain a license from Ramot with respect to such technology and the results of such further funded research in order to develop and commercialize products in the diagnostics space, and Ramot wishes to grant the Company such license, all in accordance with the terms and conditions of this R&D Agreement. Pursuant to the above noted R&D Agreement, Savicell will fund research expenditures amounting to a total of $1,600,000 according to the following schedule: $81,000 within 5 business days of the R&D Agreement (paid) Before October 2012; $359,500 plus VAT as applicable (paid) Before January 3, 2013; $359,500 plus VAT as applicable (paid) Before April 3, 2013; $400,000 plus VAT as applicable (paid) Before July 3, 2013; $400,000 plus VAT as applicable (paid) The payments originally due on April 3, 2013 and July 3, 2013 were postponed by the parties until such time as the funds were actually required in furtherance of the joint research and development initiatives. As of December 31, 2015, Savicell’s entire financing commitment has been met and no more expenditures are mandated by the R&D Agreement on behalf of Ramot. Savicell is continuing the clinical research within its own laboratory situated in Haifa, Israel. In addition, on July 24, 2012, Savicell agreed to issue to Ramot warrants (the “Warrants”) to purchase a number of ordinary shares of Savicell which shall together comprise 15% of issued shares of Savicell on an as-converted, fully diluted basis (equivalent to 1,765 Warrant Shares of Savicell). The Warrants shall be exercisable at an exercise price equal to the par value of the Warrant Shares, at any time and from time to time before Savicell completes a deemed liquidity event or the first underwritten offering of the Savicell's ordinary shares to the general public. The fair value of the Warrant Shares has been estimated at $1,698 per Warrant Share which is equivalent to the price at which Savicell has issued shares to third parties, for a total of $2,998,682 which has been included in research and development costs. As the exercise price inherent in the warrant certificate to purchase 1,765 common shares of Savicell is at nominal value, the warrant certificate is valued at the price of the subsequent equity issuance by Savicell ($1,698 per share) and the related common shares are considered to be issued and outstanding. Upon successful development and commercialization of the technology, and in recognition of the rights and licenses granted to Savicell pursuant to this R&D Agreement, Savicell will be subject to (a) royalties based on the worldwide sales related to the technology; and (b) minimum annual royalties with respect to any calendar year following the first commercial sales as follows. The minimum annual royalties are subject to increases for each successive year. During the six months ended June 30, 2017, Savicell incurred research and development costs of $609,880 (June 2016 -$673,882) which were included in the consolidated statements of operations and comprehensive loss. |
Related Party Transactions
Related Party Transactions | 6 Months Ended |
Jun. 30, 2017 | |
Related Party Transactions [Text Block] | Note 5 – Related Party Transactions The Company completed the following related party transactions: During the six months ended June 30, 2017, the Company incurred consulting fees and salaries of $239,682 (for the six months ended June 30, 2016 - $288,204) payable to its directors and officers. The Company incurred consulting fees payable to a company controlled by a former director/officer of $54,000 (for the six months ended June 30, 2016 - $54,000). As at June 30, 2017, included in accounts payable and accrued liabilities are amounts of $46,286 (December 31, 2016 – $6,300) that was payable to a company controlled by a former director/officer of the Company and $193,369 (December 31, 2016 – $34,967) that was payable to current officers or directors of the Company |
Convertible Debentures
Convertible Debentures | 6 Months Ended |
Jun. 30, 2017 | |
Convertible Debentures [Text Block] | Note 6 – Convertible Debentures On April 15, 2015, the Company entered into debt conversion option agreements with two directors, one consultant and one employee of the Company pursuant to which the Company collectively settled debts in the aggregate amount of $852,418. Pursuant to the agreements, these individuals may convert a portion or all of the debt amounts into common shares of the Company at a price per share of $0.055 over a seven year term. On December 31, 2015, the Company entered into debt conversion option agreements with two directors, one consultant and one employee of the Company pursuant to which the Company collectively settled debts in the aggregate amount of $188,085 with an unsecured and non-interest bearing convertible debenture. Pursuant to the agreements, these individuals may convert a portion or all of the debt amounts into common shares of the Company at a price per share of $0.20 over a seven year term. On December 31, 2016, the Company entered into debt conversion option agreements with two directors, one consultant and one employee of the Company pursuant to which the Company collectively settled debts in the aggregate amount of $172,895 with an unsecured and non-interest bearing convertible debenture. Pursuant to the agreements, these individuals may convert a portion or all of the debt amounts into common shares of the Company at a price per share of $0.20 over a seven-year term. The Company evaluated these convertible debentures for derivatives and determined that they do not qualify for derivative treatment. The Company then evaluated the debenture for beneficial conversion features and determined that the convertible loan issued on April 15, 2015 does contain beneficial conversion features. The aggregate intrinsic value of the beneficial conversion features was determined to be $852,418. This amount was recorded as a debt discount on April 15, 2015 that is being amortized over the life of the debenture at effective interest rate of 77%. Total debt discount amortization during the six months ended June 30, 2017 was $140,182. (December 31, 2016 – $368,496) December 31, 2016 Additions June 30, 2017 Convertible debentures $ 1,213,397 - 1,213,397 Convertible discount (852,418 ) - (852,418 ) Net convertible debentures 360,979 - 360,979 Interest accretion 368,496 140,182 508,678 Balance $ 729,475 64,098 869,657 |
Equity
Equity | 6 Months Ended |
Jun. 30, 2017 | |
Equity [Text Block] | Note 7 –Equity Common shares The Company has authorized 500,000,000 common shares at par value of $0.001 per share. On April 19, 2015, the Company issued 3,550,000 common shares at $0.20 per share for total proceeds of $710,000. On May 22, 2015, the Company issued 500,000 common shares at $0.20 per share for total proceeds of $100,000. On May 28, 2015, the Company entered into a debt settlement agreement pursuant to which the Company settled a related party term loan in the aggregate amount of $74,062 by the issuance of 462,890 common shares at $0.20 per share. On June 23 2015, stock options previously granted by the Company were exercised resulting in the issuance of 481,179 common shares at $0.01 per share for total proceeds of $4,812. On June 23, 2015, stock options previously granted by the Company were exercised resulting in the issuance of 100,000 common shares at $0.01 per share for total proceeds of $1,000. On June 25, 2015, the Company issued 5,000,000 common shares at $0.20 per share for total proceeds of $1,000,000. On July 20, 2015, four shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 3,824,922 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $611,987. On September 3, 2015, three shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 1,786,250 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $285,800. On October 20, 2015, two shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 637,500 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $102,000. As at January 31, 2016, three shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 1,756,619 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $281,059. On March 31, 2016, one shareholder of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 2,198,819 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $351,811. On March 31, 2016, one shareholder of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 318,742 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $50,999. On April 18, 2016, the Company issued 625,000 common shares at $0.20 per share for total proceeds of $125,000. On April 21, 2016, two shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 824,992 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $131,999. On April 22, 2016, one shareholder of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 318,749 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $50,999. On June 6, 2016, eight shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 1,115,625 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $178,500. On June 14, 2016, the Company issued 2,500,000 common shares at $0.20 per share for total proceeds of $500,000. On July 5, 2016, stock options previously granted by the Company were exercised resulting in the issuance of 50,000 common shares at $0.01 per share for total proceeds of $500. On July 7, 2016, one shareholder of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 839,375 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $134,300. On September 1, 2016, eight shareholders of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 4,653,732 common shares at $0.16 per share which equals to 80% of the share pricing of the financing completed on April 19, 2015. Total book value of the issued common shares is $744,597. On April 3, 2017, one shareholder of Savicell exercised their right to convert their shareholding in Savicell into common shares of the Company. Accordingly, the Company issued 288,830 common shares at $0.16 per share. Total book value of the issued common shares is $46,212. On April 3, 2017, the Company issued 1,693,750 common shares at $0.20 per share for total proceeds of $338,750. Each unit comprises one share and one warrant to purchase a further share at a price of $0.20. Each warrant entitles the holder to acquire one additional share of common stock at a price of $0.20 per share until April 3, 2019. On May 4, 2017, the Company issued an aggregate of 1,250,000 common shares at a price of $0.20 per unit for gross proceeds of $250,000. As at June 30, 2017, the Company has 117,413,408 common shares issued and outstanding. Warrants A summary of warrants as at December 31, 2016 and June 30, 2017 is as follows: Warrant Outstanding Weighted Average Number of warrant Exercise Price Balance, December 31, 2016 - $ - Issued 1,693,750 0.20 Balance, June 30, 2017 1,693,750 $ 0.20 Number Exercise Expiry Outstanding 1 Price Date 1,693,750 $0.20 April 3, 2019 Preferred Shares The Company has authorized 20,000,000 preferred shares at a par value of $0.001 per share. No preferred shares have been issued by the Company and accordingly none are outstanding. Stock Options On May 28, 2013, the Company granted a total of 962,358 stock options to a consultant. The stock options are exercisable at an exercise price of $0.01 per share and may be exercised for five years. A quarter of the options will vest on each of the first four anniversaries of the date of initial grant. The options were valued based on the Black Scholes model. On June 22, 2015, 481,179 of these options were exercised at $0.01 per share for total proceeds of $4,812. For the six months ended June 30, 2017 the Company recorded stock based compensation of $4,630 (2016: $17,628) for such options. On August 22, 2013, the Company granted a total of 800,000 stock options to a consultant. The stock options are exercisable at the exercise price of $0.01 per share and may be exercised for five years. 480,000 of the options so granted will vest as to one quarter of such options at the end of each completed year that the consultant provides the services. The remaining 320,000 options will be fully vested when the consultant has completed the provision of a minimum of 600 blood samples of lung cancer and control patients during the 4 years from August 22, 2013. One twelfth of these options will vest upon each 50 blood samples having been delivered by the consultant to the Company. The options were valued based on the Black Scholes model. For the six months ended June 30, 2017 the Company recorded stock based compensation of $2,819 (2016: $28,419) for such options. On November 11, 2013, the Company granted a total of 1,924,717 stock options to a consultant. The stock options are exercisable at an exercise price of $0.01 per share and may be exercised for seven years. A quarter of the options will vest immediately and a quarter on each of the first three anniversaries of the date of initial grant. The options were valued based on the Black Scholes model. As of December 31, 2016, the Company has fully recorded the stock based compensation for such options. On January 1, 2014, the Company granted a total of 500,000 stock options to a consultant. The stock options are exercisable at an exercise price of $0.01 per share and may be exercised for five years. A quarter of the options will vest immediately and a quarter will vest at end of each completed year that the consultant provides the services. The options were valued based on the Black Scholes model. As of December 31, 2016, the Company has fully recorded the stock based compensation for such options. On May 4, 2014 the Company granted a total of 150,000 stock options to a consultant. The stock options are exercisable at an exercise price of $0.01 per share and may be exercised for seven years. One third of the options will vest at end of each completed year that the consultant provides the services. The options were valued based on the Black Scholes model. For the six months ended June 30, 2017, the Company recorded stock based compensation of $68 (2016: $208) for such options. On May 15, 2014 the Company granted a total of 150,000 stock options to a consultant. The stock options are exercisable at an exercise price of $0.01 per share and may be exercised for five years. 25,000 of the options will vest immediately. Furthermore, 75,000 and 50,000 of the options respectively will vest on the first and second anniversaries that the consultant provides the services. The options were valued based on the Black Scholes model. As of December 31, 2016, the Company has fully recorded the stock based compensation for such options. In addition, on June 23, 2015, 100,000 of these options were exercised at $0.01 per share for total proceeds of $1,000. On August 4, 2015 the Company granted a total of 150,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for six years. One third of the options will vest at end of each of June 21, 2016, June 21, 2017 and June 21, 2018 that the employee remains an employee of the Company or its subsidiaries. On April 20, 2017, the Company amended this option agreement resulting in the immediate vesting of any remainder unvested options upon termination of employment. In addition, the expiration date of these options were revised to be three years from the date of termination. These options became fully vested as at April 23, 2017. The options were valued based on the Black Scholes model. For the six months ended June 30, 2017, the Company recorded stock based compensation of $7,843 (2016: $9,347) for such options. In August 2015 the Company granted a total of 1,730,000 stock options to four advisors of the Company. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for six-seven years. One third of the options will vest at end of each completed year for which the consultant provides the services. The options were valued based on the Black Scholes model. For the six months ended June 30, 2017, the Company recorded stock based compensation of $22,367 (2016: $107,843) for such options. On September 1, 2015 the Company granted a total of 150,000 stock options to two employees. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One third of the options will vest at the grant date of each of September 1, 2015, September 1, 2016 and September 1, 2017 that the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the six months ended June 30, 2017, the Company recorded stock based compensation of $4,891 (2016: $12,098) for such options. On November 22, 2015 the Company granted a total of 50,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One third of the options will vest at the grant date of each of November 22, 2016, November 22, 2017 and November 22, 2018 that the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the six months ended June 30, 2017, the Company recorded stock based compensation of $1,063 (2016: $4,482) for such options. On December 1, 2015 the Company granted a total of 125,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One third of the options will vest at the grant date of each of December 1, 2016, December 1, 2017 and December 1, 2018 that the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the six months ended June 30, 2017, the Company recorded stock based compensation of $2,683 (2016: $11,393) for such options. On December 6, 2015 the Company granted a total of 100,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One third of the options will vest at the grant date of each of December 6, 2016, December 6, 2017 and December 6, 2018 that the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the six months ended June 30, 2017, the Company recorded stock based compensation of $2,207 (2016: $9,436) for such options. On February 15, 2016 the Company granted a total of 50,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One third of the options will vest on each of the first, second and third anniversaries of the date of grant provided the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the six months ended June 30, 2017, the Company recorded stock based compensation of $971 (2016: $2,895) for such options. On March 7, 2016 the Company granted a total of 75,000 stock options to two employees. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One third of the options will vest on each of the first, second and third anniversaries of the date of grant provided the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the six months ended June 30, 2017, the Company recorded stock based compensation of $1,641 (2016: $4,425) for such options. On May 5, 2016 the Company granted a total of 150,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for ten years. One third of the options will vest on each of the first, second and third anniversaries of the date of grant provided the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the six months ended June 30, 2017 the Company recorded stock based compensation of $5,845 (2016: $13,385) for such options. On June 6, 2016 the Company granted a total of 800,000 stock options to a consultant. The stock options are exercisable at the exercise price of $0.20 per share and may be exercised for five years. 480,000 of the options so granted will vest as to one quarter of such options at the end of each completed year that the consultant provides the services. The remaining 320,000 options will be fully vested when the consultant has completed the provision of a minimum of 600 blood samples of lung cancer and control patients during the 4 years following June 6, 2016. One twelfth of these options will vest upon each 50 blood samples having been delivered by the consultant to the Company. The options were valued based on the Black Scholes model. For the six months ended June 30, 2017, the Company recorded stock based compensation of $15,843 (2016: $23,746) for such options. On November 1, 2016, the Company granted a total of 360,000 stock options to an employee. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One half of the options will vest immediately and one-half shall vest on the on the first anniversary date of grant provided the grantee remains a board member of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the six months ended June 30, 2017, the Company recorded stock based compensation of $12,754 (2016: $29,946) for such options. On May 31, 2017, the Company granted a total of 875,000 stock options to six employees. The stock options are exercisable at an exercise price of $0.20 per share and may be exercised for seven years. One third of the options will vest on each of the first, second and third anniversaries of the date of grant, namely May 31, 2018, May 31, 2019 and May 31, 2020 provided the employee remains an employee of the Company or its subsidiaries. The options were valued based on the Black Scholes model. For the six months ended June 30, 2017, the Company recorded stock based compensation of $4,965 for such options. The fair value of each option grant is calculated using the following assumptions: 2017 2016 Expected life – year 0.9 - 8.8 3 - 10 Interest rate 1.01 – 2.31% 0.73 - 2.45% Volatility 67.24 - 106.88% 65.99 - 99.04% Dividend yield - -% - -% Forfeiture rate - -% - -% Number of Options Weighted Expire date Average Exercise Price Balance, December 31, 2014 14,237,075 $ 0.01 Exercised, on June 23, 2015 (481,179 ) 0.01 Exercised, on June 25, 2015 (100,000 ) 0.01 Granted, on August 4, 2015 150,000 0.20 April 23, 2020 Granted, on August 7, 2015 1,610,000 0.20 August 7, 2022 Granted, on August 25, 2015 120,000 0.20 August 25, 2022 Granted, on September 1, 2015 150,000 0.20 September 1, 2022 Granted, on November 22, 2015 50,000 0.20 November 22, 2022 Granted, on December 1, 2015 125,000 0.20 December 1, 2022 Granted, on December 6, 2015 100,000 0.20 December 6, 2022 Balance, December 31, 2015 15,960,896 $ 0.04 Granted, on February 15, 2016 50,000 0.20 February 15, 2023 Granted, on March 7, 2016 75,000 0.20 March 7, 2023 Granted, on May 5, 2016 150,000 0.20 May 5, 2026 Granted, on June 6, 2016 800,000 0.20 June 6, 2021 Exercised, on July 7, 2016 (50,000 ) 0.01 Granted, on November 1, 2016 360,000 0.20 October 31, 2023 Balance, December 31, 2016 17,345,896 $ 0.05 Granted, on May 31, 2017 875,000 0.20 May 31, 2024 Balance, June 30, 2017 18,220,896 $ 0.06 Outstanding June 30, 2017 Exercisable as at June 30, 2017 Weighted Weighted Weighted Average Weighted Average Average Remaining Average Remaining Exercise Number of Exercise Contractual Number of Exercise Contractual Price Options Price Life (years) Options Price Life (years) $ 0.01 9,750,000 $ 0.01 5.18 9,750,000 $ 0.01 5.18 0.01 481,179 0.01 0.91 481,179 0.01 0.91 0.01 800,000 0.01 1.15 680,001 0.01 1.15 0.01 1,924,717 0.01 3.37 1,924,717 0.01 3.37 0.01 500,000 0.01 1.51 500,000 0.01 1.51 0.01 150,000 0.01 3.85 150,000 0.01 3.85 0.20 150,000 0.20 2.82 150,000 0.20 2.82 0.20 120,000 0.20 5.16 40,000 0.20 5.16 0.20 1,610,000 0.20 5.11 536,667 0.20 5.11 0.20 150,000 0.20 5.18 100,000 0.20 5.18 0.20 50,000 0.20 5.40 16,667 0.20 5.40 0.20 125,000 0.20 5.42 41,667 0.20 5.42 0.20 100,000 0.20 5.44 33,333 0.20 5.44 0.20 50,000 0.20 5.63 16,667 0.20 5.63 0.20 75,000 0.20 5.69 25,000 0.20 5.69 0.20 150,000 0.20 8.85 70,000 0.20 8.85 0.20 800,000 0.20 3.94 173,334 0.20 3.94 0.20 360,000 0.20 6.34 180,000 0.20 6.34 0.20 875,000 0.20 6.92 - - - 18,220,896 $ 0.06 4.64 14,869,232 $ 0.03 4.47 Outstanding as at December 31, 2016 Exercisable as at December 31, 2016 Weighted Weighted Weighted Average Weighted Average Average Remaining Average Remaining Exercise Number of Exercise Contractual Number of Exercise Contractual Price Options Price Life (years) Options Price Life (years) $ 0.01 9,750,000 $ 0.01 5.67 9,750,000 $ 0.01 5.67 0.01 481,179 0.01 1.41 240,589 0.01 1.41 0.01 800,000 0.01 1.64 680,001 0.01 1.64 0.01 1,924,717 0.01 3.87 1,924,717 0.01 3.87 0.01 500,000 0.01 2.00 500,000 0.01 2.00 0.01 150,000 0.01 4.34 100,000 0.01 4.34 0.20 150,000 0.20 4.34 50,000 0.20 4.34 0.20 120,000 0.20 5.65 40,000 0.20 5.65 0.20 1,610,000 0.20 5.60 536,667 0.20 5.60 0.20 150,000 0.20 5.67 100,000 0.20 5.67 0.20 50,000 0.20 5.90 16,667 0.20 5.90 0.20 125,000 0.20 5.92 41,667 0.20 5.92 0.20 100,000 0.20 5.93 33,333 0.20 5.93 0.20 50,000 0.20 6.13 - - - 0.20 75,000 0.20 6.18 - - - 0.20 150,000 0.20 9.35 30,000 0.20 9.35 0.20 800,000 0.20 4.43 26,667 0.20 4.43 0.20 360,000 0.20 6.84 180,000 0.20 6.84 17,345,896 $ 0.05 5.03 14,250,308 $ 0.02 5.04 Non-Controlling Interests The Company’s subsidiary, Savicell, granted a third party a warrant certificate to purchase 1,765 common shares of Savicell that initially represented 15% of the underlying common equity of Savicell. In the course of its initial equity issuances up to October 30, 2012 (the “Initial Closing”), Savicell issued a total of 592 ordinary shares at $1,698.97 per share to the non-related third party representing approximately 4.79% of the fully diluted common equity of Savicell for aggregate proceeds of $1,005,795. The Savicell investors are entitled to convert their Savicell shares into common shares of ODT at a price equal to 80% of the per share pricing of the first completed ODT financing of over $500,000 conducted after July 1, 2012 (the “Financing Price”) provided that for purposes of such conversion, the deemed maximum Financing Price shall be the per share price of the common shares of ODT based on (a) an aggregate ODT equity valuation of $30,000,000 ; and (b) the number of common shares of ODT outstanding at the time of the financing. Savicell continued its equity issuances following the Initial Closing. As at December 31, 2012, Savicell had issued a total of 684 shares at $1,698.97 per share representing approximately 5.11% of the fully diluted common equity of Savicell for aggregate proceeds of $1,162,192. During the year ended December 31, 2013, Savicell issued a total of 760 shares at $1,700 per share representing approximately 5.68% of the fully diluted common equity of Savicell for aggregate proceeds of $1,292,000. During the year ended December 31, 2014, Savicell issued a total of 183 shares at $1,699 per share representing approximately 1.37% of the fully diluted common equity of Savicell for aggregate proceeds of $310,977. During the year ended December 31, 2015, Savicell issued a total of 417 shares at $1,700 per share to third parties for aggregate proceeds of $709,087. As at December 31, 2015, Savicell also issued 516 shares at $1,700 to ODT, which of $532,084 has not been received as at December 31, 2015. In addition, Savicell investors exchanged 588 Savicell shares for 6,248,672 of ODT common shares with ODT receiving the Savicell shares so exchanged. Following these share issuances, the Company, the Warrant holder and the Savicell investors held underlying interests in the equity of Savicell of 77.00%, 12.6% and 10.4% respectively (December 31, 2014- 74.67%, 13.18% and 12.15%) . During the year ended December 31, 2016, Savicell investors exchanged 1,132 Savicell shares for 12,026,654 of ODT common shares with ODT receiving the Savicell shares so exchanged. As at December 31, 2016, Savicell received $1,786,656 from ODT and issued 1,051 shares to ODT in return. Following these share issuances, the Company, the Warrant holder and the Savicell investors held underlying interests in the equity of Savicell of 86.13%, 11.72% and 2.15%, respectively (December 31, 2015- 77%, 12.6% and 10.4%) . As a result, ODT’s shareholding increased, which increased the additional paid-in capital during the year. As at June 30, 2017, the Company, the Warrant holder and the Savicell investors held underlying interests in the equity of Savicell of 86.31%, 11.72% and 1.97%, respectively (December 31, 2016 - 86.13%, 11.72% and 2.15%) . Savicell’s Common Shares Number Amount of Shares Balance, December 31, 2013 13,209 $ 2,454,192 Issued for cash pursuant to share subscriptions 183 310,977 Balance, December 31, 2014 13,392 2,765,169 Issued for cash pursuant to share subscriptions 730 1,241,171 Shares issued to settle inter-company debts 203 345,198 Share subscription receivable (313 ) (532,084 ) Balance, December 31, 2015 14,012 $ 3,819,454 Shares issued to settle inter-company debts 1,051 1,786,656 Balance, June 30, 2017 and December 31, 2016 15,063 $ 5,606,110 As the exercise price inherent in the warrant certificate to purchase 1,765 common shares of Savicell is at nominal value, the warrant certificate is valued at the price of the subsequent equity issuance by Savicell ($1,698 per share) and the related common shares are considered to be issued and outstanding. |
Commitments And Guarantees
Commitments And Guarantees | 6 Months Ended |
Jun. 30, 2017 | |
Commitments And Guarantees [Text Block] | Note 8 – Commitments and Guarantees The Company did not become a guarantor to any parties as at June 30, 2017. 1. On September 11, 2012, ODT signed an employment agreement with Giora Davidovits, its chief executive officer and President, which agreement entailed an effective date of September 1, 2012. In return for acting as its chief executive officer, the Company will provide Mr. Davidovits an annual salary of $250,000 together with other benefits and the potential for additional bonuses as declared from time to time by the Company’s board of directors. The agreement is effective until August 31, 2017 unless terminated early in accordance with the termination provisions contained within the employment agreement and subject to agreed severance amounts. In connection with the execution of the employment agreement, the Company issued to Giora Davidovits options to purchase 3,750,000 common shares at a price per share of $0.01. The options are exercisable for 10 years. Mr. Davidovits is eligible for subsequent option grants at the discretion of the board of directors. 2. On October 30, 2012, ODT and Savicell signed an employment agreement with Eyal Davidovits, its chief operating officer, which agreement entailed an effective date of September 1, 2012. In return for acting as its chief operating officer, the Company will provide Mr. Davidovits an annual salary of $112,324 (NIS 432,000), together with other fringe benefits including those related to the use of an automobile, health insurance, contributions to government run retirement programs and the potential for additional bonuses as declared from time to time by the Company’s board of directors. The agreement is effective until August 31, 2017 unless terminated early in accordance with the termination provisions contained within the employment agreement and subject to agreed severance amounts. In connection with the execution of the employment agreement, the Company issued to Eyal Davidovits options to purchase 2,750,000 common shares at a price per share of $0.01. The options are exercisable for 10 years. Mr. Davidovits is eligible for subsequent option grants at the discretion of the board of directors. 3. On November 8, 2012, ODT and Savicell signed an employment agreement with Dr. Irit Arbel, its vice president, research and development, which agreement entailed an effective date of September 1, 2012. In return for acting as its new vice president, research and development officer, the Company will provide Dr. Arbel an annual salary of $106,084 (NIS 408,000) together with other fringe benefits, health insurance, contributions to government run retirement programs and the potential for additional bonuses as declared from time to time by the Company’s board of directors. The agreement is effective until August 31, 2017 unless terminated early in accordance with the termination provisions contained within the employment agreement and subject to agreed severance amounts. In connection with the execution of the employment agreement, the Company issued to Irit Arbel options to purchase 2,000,000 common shares at a price per share of $0.01. The options are exercisable for 10 years. Dr. Arbel is eligible for subsequent option grants at the discretion of the board of directors. 4. On July 20, 2015, the Company signed an operating lease agreement to lease offices for a period ending July 31, 2018 with an option to renew the lease for an additional period of 2 years. The monthly lease expense is $3,152 (NIS 12,121). Future minimum lease commitment under the operating lease agreement is approximately $59,888 (NIS 339,388). The Company pledged a bank deposit which is used as a bank guarantee at an amount of $13,254 (NIS 50,000) to secure its payments under the lease agreement. The minimum future payments for the above commitments are as follows: Consulting fee and Year Salaries Office rent Total 2017 $ 312,272 $ 37,824 $ 350,096 2018 - 22,064 22,064 Total $ 312,272 $ 59,888 $ 372,160 |
Geographic Information
Geographic Information | 6 Months Ended |
Jun. 30, 2017 | |
Geographic Information [Text Block] | Note 9 – Geographic Information The Company’s head office is located in the United States (“US”). The operations of the Company are primarily in two geographic areas: the US and Israel. A summary of geographical information for the Company’s long lived assets is as follows: Period ended June 30, 2017 US Israel Total Long-live assets $ - $ 53,828 $ 53,828 Year ended December 31, 2016 US Israel Total Long-live assets $ - $ 55,444 $ 55,444 |
Subsequent Events
Subsequent Events | 6 Months Ended |
Jun. 30, 2017 | |
Subsequent Events [Text Block] | Note 10 – Subsequent Events 1. On July 2, 2017, the Company granted options to purchase 150,000 shares of its common stock to a new employee, pursuant to an employment agreement. The exercise price of the options is $0.20 per share and may be exercised for three years. The options vest on each of July 2, 2018, July 2, 2019 and July 2, 2020 provided that the employee remains an employee of the Company. 2. On August 3, 2017, the Company entered into two subscription agreements with two parties in which the company shall receive an aggregate $120,000 toward the subscription of 600,000 common shares at a share price of $0.20 per share. |
Summary of Significant Accounti
Summary of Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2017 | |
Basis of Presentation [Policy Text Block] | a) Basis of Presentation |
Principles of Consolidation [Policy Text Block] | b) Principles of Consolidation |
Use of Estimates [Policy Text Block] | c) Use of Estimates Significant areas requiring the use of management estimates include assumptions and estimates relating to share-based payments, valuation allowances for deferred income tax assets and determination of useful lives of property, plant and equipment. |
Foreign Currency Translation [Policy Text Block] | d) Foreign Currency Translation The Company’s subsidiary’s functional currency is the New Israeli Shekel (“NIS”). All transactions are recorded in NIS. Monetary assets and liabilities denominated in NIS are translated into U.S. dollars at rates of exchange in effect at the balance sheet dates and expenses are translated at the average exchange rates. Gains and losses from such translations are included in stockholders’ equity, as a component of other comprehensive income. In the year ended 2013, Savicell’s functional currency was the U.S. dollar. During the year 2014, with the increased volume of transactions in the local currency, the management reassessed Savicell’s functional currency to NIS based on the change in facts and effective as of January 1, 2014. Such change is still appropriate in 2016. As a result of the functional currency change discussed above, a cumulative translation adjustment of $18,946 is included in accumulated other comprehensive income and will only be adjusted in the event of a full or partial disposition of the Company's investment in Savicell. |
Cash and Cash Equivalents [Policy Text Block] | e) Cash and Cash Equivalents |
Stock-based Compensation [Policy Text Block] | f) Stock-based Compensation Share-based payments issued to non-employees are recorded at their fair values at each reporting date, as the equity instruments vest and are recognized as expense over the related service period in accordance with the provisions of ASC 718 and ASC Topic 505, Equity. For equity instruments granted to non-employees, the Company recognizes stock-based compensation expense on a straight-line basis. |
Income Taxes [Policy Text Block] | g) Income Taxes Per FASB ASC 740 “Income taxes” under the liability method, it is the Company’s policy to provide for uncertain tax positions and the related interest and penalties based upon management’s assessment of whether a tax benefit is more likely than not to be sustained upon examination by tax authorities. At June 30, 2017, the Company believes it has appropriately accounted for any unrecognized tax benefits. To the extent the Company prevails in matters for which a liability for an unrecognized benefit is established or is required to pay amounts in excess of the liability, the Company’s effective tax rate in a given financial statement period may be affected. Interest and penalties associated with the Company’s tax positions are recorded as Interest Expense. |
Comprehensive Income (Loss) [Policy Text Block] | h) Comprehensive Income (Loss) |
Earnings (Loss) Per Share [Policy Text Block] | i) Earnings (Loss) Per Share Diluted loss per share is computed on the basis of the weighted average number of common shares and dilutive securities outstanding. Stock options are considered to be common stock equivalents and were not included in the net loss per share calculation for the six months ended June 30, 2017 and 2016 because the inclusion of such underlying shares would have had an anti-dilutive effect. |
Financial Instruments and Fair Value of Financial Instruments [Policy Text Block] | j) Financial Instruments and Fair Value of Financial Instruments - Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. - Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. - Level 3 inputs to valuation methodology are unobservable and significant to the fair measurement. As at June 30, 2017, the fair value of cash and cash equivalents was measured using Level 1 inputs. The Company’s financial instruments are cash and cash equivalents, restricted cash, VAT receivables, accounts payable and accrued liabilities and convertible debentures. The recorded values of cash and cash equivalents and accounts payable and accrued liabilities approximate their fair values based on their short-term nature. The Company believes the recorded values of convertible debentures, net of the discount, approximate the fair value as the interest rate (stated or effective) approximates market rates for similar types of instruments. |
Research and Development Costs [Policy Text Block] | k) Research and Development Costs Three Months Ended Three Months Ended Six Months Ended Six Months Ended June 30, 2017 June 30, 2016 June 30, 2017 June 30, 2016 Research and Development $ $ $ $ Expenses Consulting fees 33,372 56,103 58,190 70,795 Legal fees 15,621 8,138 22,330 8,138 Office and Miscellaneous Expense 6,135 - 9,936 6,314 Payroll expense 236,279 181,166 361,114 331,632 R&D materials and supplies 11,387 68,417 42,604 88,684 Rent 8,579 6,907 19,535 17,912 Share-based compensation 47,747 77,679 89,392 150,406 6,779 Insurance - 6,779 - Total 365,899 398,410 609,880 673,881 Savicell’s financing commitment related to the License and Research Funding Agreement (as defined in Note 4 below) entered into with Ramot at Tel Aviv University was completely fulfilled by December 31, 2015. |
Fixed Assets [Policy Text Block] | l) Fixed Assets Class of Properties Amortization Rate Furniture and Fixtures 15 -year; straight-line basis Computer Equipment 3 to 4 -year; straight-line basis Lab Equipment 3 to 15 -year; straight-line basis |
Convertible debentures [Policy Text Block] | m) Convertible debentures |
Modifications to debt [Policy Text Block] | n) Modifications to debt |
Recently Adopted Accounting Pronouncements [Policy Text Block] | o) Recently Adopted Accounting Pronouncements |
Recently Issued Accounting Pronouncements [Policy Text Block] | p) Recently Issued Accounting Pronouncements On November 17, 2016, the FASB issued ASU 2016-18, Restricted Cash. Entities will be required to show the changes in the total of cash, cash equivalents, restricted cash and restricted cash equivalents in the statement of cash flows. As a result, entities will no longer present transfers between cash and cash equivalents and restricted cash and restricted cash equivalents in the statement of cash flows. The Company is currently evaluating the impact of the adoption of this guidance on its consolidated financial statements, if any. In March 2016, the FASB issued ASU 2016-02, Leases, which supersedes ASC Topic 840, Leases, and sets forth the principles for the recognition, measurement, presentation, and disclosure of leases for both lessees and lessors. ASU 2016-02 requires lessees to classify leases as either finance or operating leases and to record on the balance sheet a right-of-use asset and a lease liability, equal to the present value of the remaining lease payments, for all leases with a term greater than 12 months regardless of the lease classification. The lease classification will determine whether the lease expense is recognized based on an effective interest rate method or a straight-line basis over the term of the lease. ASU 2016-02 will be effective for us beginning January 1, 2019, with early adoption permitted. Entities are required to use a modified retrospective transition method for existing leases. We are currently evaluating the potential impact this guidance will have on our consolidated financial statements. In January 2016, the FASB issued ASU 2016-01, Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The amendments to the guidance enhance the reporting model for financial instruments, which includes amendments to address aspects of recognition, measurement, presentation, and disclosure. The updated guidance is effective for us beginning January 1, 2018. We do not expect this guidance to have a material impact on our consolidated financial statements. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers, as a new Topic, ASC 606. The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. Companies may apply the new guidance using either the full retrospective transition method, which requires restating each prior period presented, or the modified retrospective transition method, under which the new guidance is applied to the current period presented in the financial statements and a cumulative-effect adjustment is recorded as of the date of adoption. We are currently evaluating the potential impact this guidance will have on our consolidated financial statements. |
Significant Accounting Polici17
Significant Accounting Policies (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Schedule of Research and Development Costs [Table Text Block] | Three Months Ended Three Months Ended Six Months Ended Six Months Ended June 30, 2017 June 30, 2016 June 30, 2017 June 30, 2016 Research and Development $ $ $ $ Expenses Consulting fees 33,372 56,103 58,190 70,795 Legal fees 15,621 8,138 22,330 8,138 Office and Miscellaneous Expense 6,135 - 9,936 6,314 Payroll expense 236,279 181,166 361,114 331,632 R&D materials and supplies 11,387 68,417 42,604 88,684 Rent 8,579 6,907 19,535 17,912 Share-based compensation 47,747 77,679 89,392 150,406 6,779 Insurance - 6,779 - Total 365,899 398,410 609,880 673,881 |
Schedule of Properties Estimated Useful life [Table Text Block] | Class of Properties Amortization Rate Furniture and Fixtures 15 -year; straight-line basis Computer Equipment 3 to 4 -year; straight-line basis Lab Equipment 3 to 15 -year; straight-line basis |
Fixed Assets (Tables)
Fixed Assets (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Schedule of Property, Plant and Equipment [Table Text Block] | Furniture and Computer Cost: Fixtures Equipment Lab Equipment Total December 31, 2016 $ 3,496 $ 26,489 $ 44,432 $ 74,417 Exchange difference 357 2,697 4,523 7,577 June 30, 2017 $ 3,853 $ 29,186 $ 48,955 $ 81,994 Furniture and Computer Amortization: Fixtures Equipment Lab Equipment Total December 31, 2016 $ 404 $ 10,645 $ 7,924 $ 18,973 Additions 207 3,818 2,890 6,915 Exchange difference 52 1,276 950 2,278 June 30, 2017 $ 663 $ 15,739 $ 11,764 $ 28,166 Furniture and Computer Net Book Value: Fixtures Equipment Lab Equipment Total December 31, 2016 $ 3,092 $ 15,844 $ 36,508 $ 55,444 June 30, 2017 $ 3,190 $ 13,447 $ 37,191 $ 53,828 |
Convertible Debentures (Tables)
Convertible Debentures (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Schedule of Convertible Debt [Table Text Block] | December 31, 2016 Additions June 30, 2017 Convertible debentures $ 1,213,397 - 1,213,397 Convertible discount (852,418 ) - (852,418 ) Net convertible debentures 360,979 - 360,979 Interest accretion 368,496 140,182 508,678 Balance $ 729,475 64,098 869,657 |
Equity (Tables)
Equity (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2017 | Dec. 31, 2016 | |
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block] | Warrant Outstanding Weighted Average Number of warrant Exercise Price Balance, December 31, 2016 - $ - Issued 1,693,750 0.20 Balance, June 30, 2017 1,693,750 $ 0.20 | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Number Exercise Expiry Outstanding 1 Price Date 1,693,750 $0.20 April 3, 2019 | |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | 2017 2016 Expected life – year 0.9 - 8.8 3 - 10 Interest rate 1.01 – 2.31% 0.73 - 2.45% Volatility 67.24 - 106.88% 65.99 - 99.04% Dividend yield - -% - -% Forfeiture rate - -% - -% | |
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | Number of Options Weighted Expire date Average Exercise Price Balance, December 31, 2014 14,237,075 $ 0.01 Exercised, on June 23, 2015 (481,179 ) 0.01 Exercised, on June 25, 2015 (100,000 ) 0.01 Granted, on August 4, 2015 150,000 0.20 April 23, 2020 Granted, on August 7, 2015 1,610,000 0.20 August 7, 2022 Granted, on August 25, 2015 120,000 0.20 August 25, 2022 Granted, on September 1, 2015 150,000 0.20 September 1, 2022 Granted, on November 22, 2015 50,000 0.20 November 22, 2022 Granted, on December 1, 2015 125,000 0.20 December 1, 2022 Granted, on December 6, 2015 100,000 0.20 December 6, 2022 Balance, December 31, 2015 15,960,896 $ 0.04 Granted, on February 15, 2016 50,000 0.20 February 15, 2023 Granted, on March 7, 2016 75,000 0.20 March 7, 2023 Granted, on May 5, 2016 150,000 0.20 May 5, 2026 Granted, on June 6, 2016 800,000 0.20 June 6, 2021 Exercised, on July 7, 2016 (50,000 ) 0.01 Granted, on November 1, 2016 360,000 0.20 October 31, 2023 Balance, December 31, 2016 17,345,896 $ 0.05 Granted, on May 31, 2017 875,000 0.20 May 31, 2024 Balance, June 30, 2017 18,220,896 $ 0.06 | |
Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] | Outstanding June 30, 2017 Exercisable as at June 30, 2017 Weighted Weighted Weighted Average Weighted Average Average Remaining Average Remaining Exercise Number of Exercise Contractual Number of Exercise Contractual Price Options Price Life (years) Options Price Life (years) $ 0.01 9,750,000 $ 0.01 5.18 9,750,000 $ 0.01 5.18 0.01 481,179 0.01 0.91 481,179 0.01 0.91 0.01 800,000 0.01 1.15 680,001 0.01 1.15 0.01 1,924,717 0.01 3.37 1,924,717 0.01 3.37 0.01 500,000 0.01 1.51 500,000 0.01 1.51 0.01 150,000 0.01 3.85 150,000 0.01 3.85 0.20 150,000 0.20 2.82 150,000 0.20 2.82 0.20 120,000 0.20 5.16 40,000 0.20 5.16 0.20 1,610,000 0.20 5.11 536,667 0.20 5.11 0.20 150,000 0.20 5.18 100,000 0.20 5.18 0.20 50,000 0.20 5.40 16,667 0.20 5.40 0.20 125,000 0.20 5.42 41,667 0.20 5.42 0.20 100,000 0.20 5.44 33,333 0.20 5.44 0.20 50,000 0.20 5.63 16,667 0.20 5.63 0.20 75,000 0.20 5.69 25,000 0.20 5.69 0.20 150,000 0.20 8.85 70,000 0.20 8.85 0.20 800,000 0.20 3.94 173,334 0.20 3.94 0.20 360,000 0.20 6.34 180,000 0.20 6.34 0.20 875,000 0.20 6.92 - - - 18,220,896 $ 0.06 4.64 14,869,232 $ 0.03 4.47 | Outstanding as at December 31, 2016 Exercisable as at December 31, 2016 Weighted Weighted Weighted Average Weighted Average Average Remaining Average Remaining Exercise Number of Exercise Contractual Number of Exercise Contractual Price Options Price Life (years) Options Price Life (years) $ 0.01 9,750,000 $ 0.01 5.67 9,750,000 $ 0.01 5.67 0.01 481,179 0.01 1.41 240,589 0.01 1.41 0.01 800,000 0.01 1.64 680,001 0.01 1.64 0.01 1,924,717 0.01 3.87 1,924,717 0.01 3.87 0.01 500,000 0.01 2.00 500,000 0.01 2.00 0.01 150,000 0.01 4.34 100,000 0.01 4.34 0.20 150,000 0.20 4.34 50,000 0.20 4.34 0.20 120,000 0.20 5.65 40,000 0.20 5.65 0.20 1,610,000 0.20 5.60 536,667 0.20 5.60 0.20 150,000 0.20 5.67 100,000 0.20 5.67 0.20 50,000 0.20 5.90 16,667 0.20 5.90 0.20 125,000 0.20 5.92 41,667 0.20 5.92 0.20 100,000 0.20 5.93 33,333 0.20 5.93 0.20 50,000 0.20 6.13 - - - 0.20 75,000 0.20 6.18 - - - 0.20 150,000 0.20 9.35 30,000 0.20 9.35 0.20 800,000 0.20 4.43 26,667 0.20 4.43 0.20 360,000 0.20 6.84 180,000 0.20 6.84 17,345,896 $ 0.05 5.03 14,250,308 $ 0.02 5.04 |
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block] | Number Amount of Shares Balance, December 31, 2013 13,209 $ 2,454,192 Issued for cash pursuant to share subscriptions 183 310,977 Balance, December 31, 2014 13,392 2,765,169 Issued for cash pursuant to share subscriptions 730 1,241,171 Shares issued to settle inter-company debts 203 345,198 Share subscription receivable (313 ) (532,084 ) Balance, December 31, 2015 14,012 $ 3,819,454 Shares issued to settle inter-company debts 1,051 1,786,656 Balance, June 30, 2017 and December 31, 2016 15,063 $ 5,606,110 |
Commitments And Guarantees (Tab
Commitments And Guarantees (Tables) | 6 Months Ended |
Jun. 30, 2017 | |
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block] | Consulting fee and Year Salaries Office rent Total 2017 $ 312,272 $ 37,824 $ 350,096 2018 - 22,064 22,064 Total $ 312,272 $ 59,888 $ 372,160 |
Geographic Information (Tables)
Geographic Information (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2017 | Dec. 31, 2016 | |
Long-lived Assets by Geographic Areas [Table Text Block] | Period ended June 30, 2017 US Israel Total Long-live assets $ - $ 53,828 $ 53,828 | Year ended December 31, 2016 US Israel Total Long-live assets $ - $ 55,444 $ 55,444 |
Nature of Operations and goin23
Nature of Operations and going concern (Narrative) (Details) | 6 Months Ended |
Jun. 30, 2017USD ($)shares | |
Nature Of Operations And Going Concern 1 | 100.00% |
Nature Of Operations And Going Concern 2 | shares | 16,000,000 |
Nature Of Operations And Going Concern 3 | 89.00% |
Nature Of Operations And Going Concern 4 | $ 10 |
Nature Of Operations And Going Concern 5 | 430 |
Nature Of Operations And Going Concern 6 | 150,756 |
Nature Of Operations And Going Concern 7 | 305,964 |
Nature Of Operations And Going Concern 8 | 10,951,279 |
Nature Of Operations And Going Concern 9 | $ 9,982,269 |
Significant Accounting Polici24
Significant Accounting Policies (Narrative) (Details) | 6 Months Ended |
Jun. 30, 2017USD ($)yrmo | |
Significant Accounting Policies 1 | 86.31% |
Significant Accounting Policies 2 | 86.13% |
Significant Accounting Policies 3 | $ | $ 18,946 |
Significant Accounting Policies 4 | 3 |
Significant Accounting Policies 5 | yr | 15 |
Significant Accounting Policies 6 | mo | 12 |
License and Research Funding 25
License and Research Funding Agreement (Narrative) (Details) | 6 Months Ended |
Jun. 30, 2017USD ($)d$ / sharesshares | |
License And Research Funding Agreement 1 | $ 1,600,000 |
License And Research Funding Agreement 2 | $ 81,000 |
License And Research Funding Agreement 3 | d | 5 |
License And Research Funding Agreement 4 | $ 359,500 |
License And Research Funding Agreement 5 | 359,500 |
License And Research Funding Agreement 6 | 400,000 |
License And Research Funding Agreement 7 | $ 400,000 |
License And Research Funding Agreement 8 | 15.00% |
License And Research Funding Agreement 9 | 1,765 |
License And Research Funding Agreement 10 | $ 1,698 |
License And Research Funding Agreement 11 | $ 2,998,682 |
License And Research Funding Agreement 12 | shares | 1,765 |
License And Research Funding Agreement 13 | $ / shares | $ 1,698 |
License And Research Funding Agreement 14 | $ 609,880 |
License And Research Funding Agreement 15 | $ 673,882 |
Related Party Transactions (Nar
Related Party Transactions (Narrative) (Details) | 6 Months Ended |
Jun. 30, 2017USD ($) | |
Related Party Transactions 1 | $ 239,682 |
Related Party Transactions 2 | 288,204 |
Related Party Transactions 3 | 54,000 |
Related Party Transactions 4 | 54,000 |
Related Party Transactions 5 | 46,286 |
Related Party Transactions 6 | 6,300 |
Related Party Transactions 7 | 193,369 |
Related Party Transactions 8 | $ 34,967 |
Convertible Debentures (Narrati
Convertible Debentures (Narrative) (Details) | 6 Months Ended |
Jun. 30, 2017USD ($) | |
Convertible Debentures 1 | $ 852,418 |
Convertible Debentures 2 | 0.055 |
Convertible Debentures 3 | 188,085 |
Convertible Debentures 4 | 0.20 |
Convertible Debentures 5 | 172,895 |
Convertible Debentures 6 | 0.20 |
Convertible Debentures 7 | $ 852,418 |
Convertible Debentures 8 | 77.00% |
Convertible Debentures 9 | $ 140,182 |
Convertible Debentures 10 | $ 368,496 |
Equity (Narrative) (Details)
Equity (Narrative) (Details) | 6 Months Ended |
Jun. 30, 2017USD ($)yr$ / sharesshares | |
Equity 1 | shares | 500,000,000 |
Equity 2 | $ / shares | $ 0.001 |
Equity 3 | shares | 3,550,000 |
Equity 4 | $ / shares | $ 0.20 |
Equity 5 | $ 710,000 |
Equity 6 | shares | 500,000 |
Equity 7 | $ / shares | $ 0.20 |
Equity 8 | $ 100,000 |
Equity 9 | $ 74,062 |
Equity 10 | shares | 462,890 |
Equity 11 | $ / shares | $ 0.20 |
Equity 12 | shares | 481,179 |
Equity 13 | $ / shares | $ 0.01 |
Equity 14 | $ 4,812 |
Equity 15 | shares | 100,000 |
Equity 16 | $ / shares | $ 0.01 |
Equity 17 | $ 1,000 |
Equity 18 | shares | 5,000,000 |
Equity 19 | $ / shares | $ 0.20 |
Equity 20 | $ 1,000,000 |
Equity 21 | shares | 3,824,922 |
Equity 22 | $ / shares | $ 0.16 |
Equity 23 | 80.00% |
Equity 24 | $ 611,987 |
Equity 25 | shares | 1,786,250 |
Equity 26 | $ / shares | $ 0.16 |
Equity 27 | 80.00% |
Equity 28 | $ 285,800 |
Equity 29 | shares | 637,500 |
Equity 30 | $ / shares | $ 0.16 |
Equity 31 | 80.00% |
Equity 32 | $ 102,000 |
Equity 33 | shares | 1,756,619 |
Equity 34 | $ / shares | $ 0.16 |
Equity 35 | 80.00% |
Equity 36 | $ 281,059 |
Equity 37 | shares | 2,198,819 |
Equity 38 | $ / shares | $ 0.16 |
Equity 39 | 80.00% |
Equity 40 | $ 351,811 |
Equity 41 | shares | 318,742 |
Equity 42 | $ / shares | $ 0.16 |
Equity 43 | 80.00% |
Equity 44 | $ 50,999 |
Equity 45 | shares | 625,000 |
Equity 46 | $ / shares | $ 0.20 |
Equity 47 | $ 125,000 |
Equity 48 | shares | 824,992 |
Equity 49 | $ / shares | $ 0.16 |
Equity 50 | 80.00% |
Equity 51 | $ 131,999 |
Equity 52 | shares | 318,749 |
Equity 53 | $ / shares | $ 0.16 |
Equity 54 | 80.00% |
Equity 55 | $ 50,999 |
Equity 56 | shares | 1,115,625 |
Equity 57 | $ / shares | $ 0.16 |
Equity 58 | 80.00% |
Equity 59 | $ 178,500 |
Equity 60 | shares | 2,500,000 |
Equity 61 | $ / shares | $ 0.20 |
Equity 62 | $ 500,000 |
Equity 63 | shares | 50,000 |
Equity 64 | $ / shares | $ 0.01 |
Equity 65 | $ 500 |
Equity 66 | shares | 839,375 |
Equity 67 | $ / shares | $ 0.16 |
Equity 68 | 80.00% |
Equity 69 | $ 134,300 |
Equity 70 | shares | 4,653,732 |
Equity 71 | $ / shares | $ 0.16 |
Equity 72 | 80.00% |
Equity 73 | $ 744,597 |
Equity 74 | shares | 288,830 |
Equity 75 | $ / shares | $ 0.16 |
Equity 76 | $ 46,212 |
Equity 77 | shares | 1,693,750 |
Equity 78 | $ / shares | $ 0.20 |
Equity 79 | $ 338,750 |
Equity 80 | $ 0.20 |
Equity 81 | $ / shares | $ 0.20 |
Equity 82 | shares | 1,250,000 |
Equity 83 | $ / shares | $ 0.20 |
Equity 84 | $ 250,000 |
Equity 85 | shares | 117,413,408 |
Equity 86 | shares | 20,000,000 |
Equity 87 | $ / shares | $ 0.001 |
Equity 88 | shares | 962,358 |
Equity 89 | $ / shares | $ 0.01 |
Equity 90 | 481,179 |
Equity 91 | $ / shares | $ 0.01 |
Equity 92 | $ 4,812 |
Equity 93 | 4,630 |
Equity 94 | $ 17,628 |
Equity 95 | shares | 800,000 |
Equity 96 | $ / shares | $ 0.01 |
Equity 97 | 480,000 |
Equity 98 | shares | 320,000 |
Equity 99 | 600 |
Equity 100 | yr | 4 |
Equity 101 | 50 |
Equity 102 | $ 2,819 |
Equity 103 | $ 28,419 |
Equity 104 | shares | 1,924,717 |
Equity 105 | $ / shares | $ 0.01 |
Equity 106 | shares | 500,000 |
Equity 107 | $ / shares | $ 0.01 |
Equity 108 | shares | 150,000 |
Equity 109 | $ / shares | $ 0.01 |
Equity 110 | $ 68 |
Equity 111 | $ 208 |
Equity 112 | shares | 150,000 |
Equity 113 | $ / shares | $ 0.01 |
Equity 114 | 25,000 |
Equity 115 | 75,000 |
Equity 116 | 50,000 |
Equity 117 | 100,000 |
Equity 118 | $ / shares | $ 0.01 |
Equity 119 | $ 1,000 |
Equity 120 | shares | 150,000 |
Equity 121 | $ / shares | $ 0.20 |
Equity 122 | $ 7,843 |
Equity 123 | $ 9,347 |
Equity 124 | shares | 1,730,000 |
Equity 125 | $ / shares | $ 0.20 |
Equity 126 | $ 22,367 |
Equity 127 | $ 107,843 |
Equity 128 | shares | 150,000 |
Equity 129 | $ / shares | $ 0.20 |
Equity 130 | $ 4,891 |
Equity 131 | $ 12,098 |
Equity 132 | shares | 50,000 |
Equity 133 | $ / shares | $ 0.20 |
Equity 134 | $ 1,063 |
Equity 135 | $ 4,482 |
Equity 136 | shares | 125,000 |
Equity 137 | $ / shares | $ 0.20 |
Equity 138 | $ 2,683 |
Equity 139 | $ 11,393 |
Equity 140 | shares | 100,000 |
Equity 141 | $ / shares | $ 0.20 |
Equity 142 | $ 2,207 |
Equity 143 | $ 9,436 |
Equity 144 | shares | 50,000 |
Equity 145 | $ / shares | $ 0.20 |
Equity 146 | $ 971 |
Equity 147 | $ 2,895 |
Equity 148 | shares | 75,000 |
Equity 149 | $ / shares | $ 0.20 |
Equity 150 | $ 1,641 |
Equity 151 | $ 4,425 |
Equity 152 | shares | 150,000 |
Equity 153 | $ / shares | $ 0.20 |
Equity 154 | $ 5,845 |
Equity 155 | $ 13,385 |
Equity 156 | shares | 800,000 |
Equity 157 | $ / shares | $ 0.20 |
Equity 158 | 480,000 |
Equity 159 | shares | 320,000 |
Equity 160 | 600 |
Equity 161 | yr | 4 |
Equity 162 | 50 |
Equity 163 | $ 15,843 |
Equity 164 | $ 23,746 |
Equity 165 | shares | 360,000 |
Equity 166 | $ / shares | $ 0.20 |
Equity 167 | $ 12,754 |
Equity 168 | $ 29,946 |
Equity 169 | shares | 875,000 |
Equity 170 | $ / shares | $ 0.20 |
Equity 171 | $ 4,965 |
Equity 172 | shares | 1,765 |
Equity 173 | 15.00% |
Equity 174 | shares | 592 |
Equity 175 | $ / shares | $ 1,698.97 |
Equity 176 | 4.79% |
Equity 177 | $ 1,005,795 |
Equity 178 | 80.00% |
Equity 179 | $ 500,000 |
Equity 180 | $ 30,000,000 |
Equity 181 | shares | 684 |
Equity 182 | $ / shares | $ 1,698.97 |
Equity 183 | 5.11% |
Equity 184 | $ 1,162,192 |
Equity 185 | shares | 760 |
Equity 186 | $ / shares | $ 1,700 |
Equity 187 | 5.68% |
Equity 188 | $ 1,292,000 |
Equity 189 | shares | 183 |
Equity 190 | $ / shares | $ 1,699 |
Equity 191 | 1.37% |
Equity 192 | $ 310,977 |
Equity 193 | shares | 417 |
Equity 194 | $ / shares | $ 1,700 |
Equity 195 | $ 709,087 |
Equity 196 | shares | 516 |
Equity 197 | $ 1,700 |
Equity 198 | $ 532,084 |
Equity 199 | shares | 588 |
Equity 200 | 6,248,672 |
Equity 201 | 77.00% |
Equity 202 | 12.60% |
Equity 203 | 10.40% |
Equity 204 | 74.67% |
Equity 205 | 13.18% |
Equity 206 | 12.15% |
Equity 207 | shares | 1,132 |
Equity 208 | 12,026,654 |
Equity 209 | $ 1,786,656 |
Equity 210 | shares | 1,051 |
Equity 211 | 86.13% |
Equity 212 | 11.72% |
Equity 213 | 2.15% |
Equity 214 | 77.00% |
Equity 215 | 12.60% |
Equity 216 | 10.40% |
Equity 217 | 86.31% |
Equity 218 | 11.72% |
Equity 219 | 1.97% |
Equity 220 | 86.13% |
Equity 221 | 11.72% |
Equity 222 | 2.15% |
Equity 223 | shares | 1,765 |
Equity 224 | $ / shares | $ 1,698 |
Commitments And Guarantees (Nar
Commitments And Guarantees (Narrative) (Details) | 6 Months Ended |
Jun. 30, 2017USD ($)yrshares | |
Commitments And Guarantees 1 | $ 250,000 |
Commitments And Guarantees 2 | shares | 3,750,000 |
Commitments And Guarantees 3 | $ 0.01 |
Commitments And Guarantees 4 | yr | 10 |
Commitments And Guarantees 5 | $ 112,324 |
Commitments And Guarantees 6 | 432,000 |
Commitments And Guarantees 7 | shares | 2,750,000 |
Commitments And Guarantees 8 | $ 0.01 |
Commitments And Guarantees 9 | yr | 10 |
Commitments And Guarantees 10 | $ 106,084 |
Commitments And Guarantees 11 | 408,000 |
Commitments And Guarantees 12 | shares | 2,000,000 |
Commitments And Guarantees 13 | $ 0.01 |
Commitments And Guarantees 14 | yr | 10 |
Commitments And Guarantees 15 | yr | 2 |
Commitments And Guarantees 16 | $ 3,152 |
Commitments And Guarantees 17 | 12,121 |
Commitments And Guarantees 18 | $ 59,888 |
Commitments And Guarantees 19 | 339,388 |
Commitments And Guarantees 20 | $ 13,254 |
Commitments And Guarantees 21 | 50,000 |
Subsequent Events (Narrative) (
Subsequent Events (Narrative) (Details) | 6 Months Ended |
Jun. 30, 2017USD ($)$ / sharesshares | |
Subsequent Events 1 | shares | 150,000 |
Subsequent Events 2 | $ / shares | $ 0.20 |
Subsequent Events 3 | $ | $ 120,000 |
Subsequent Events 4 | shares | 600,000 |
Subsequent Events 5 | $ / shares | $ 0.20 |
Schedule of Research and Develo
Schedule of Research and Development Costs (Details) | 6 Months Ended |
Jun. 30, 2017USD ($) | |
Significant Accounting Policies Schedule Of Research And Development Costs 1 | $ 33,372 |
Significant Accounting Policies Schedule Of Research And Development Costs 2 | 56,103 |
Significant Accounting Policies Schedule Of Research And Development Costs 3 | 58,190 |
Significant Accounting Policies Schedule Of Research And Development Costs 4 | 70,795 |
Significant Accounting Policies Schedule Of Research And Development Costs 5 | 15,621 |
Significant Accounting Policies Schedule Of Research And Development Costs 6 | 8,138 |
Significant Accounting Policies Schedule Of Research And Development Costs 7 | 22,330 |
Significant Accounting Policies Schedule Of Research And Development Costs 8 | 8,138 |
Significant Accounting Policies Schedule Of Research And Development Costs 9 | 6,135 |
Significant Accounting Policies Schedule Of Research And Development Costs 10 | 0 |
Significant Accounting Policies Schedule Of Research And Development Costs 11 | 9,936 |
Significant Accounting Policies Schedule Of Research And Development Costs 12 | 6,314 |
Significant Accounting Policies Schedule Of Research And Development Costs 13 | 236,279 |
Significant Accounting Policies Schedule Of Research And Development Costs 14 | 181,166 |
Significant Accounting Policies Schedule Of Research And Development Costs 15 | 361,114 |
Significant Accounting Policies Schedule Of Research And Development Costs 16 | 331,632 |
Significant Accounting Policies Schedule Of Research And Development Costs 17 | 11,387 |
Significant Accounting Policies Schedule Of Research And Development Costs 18 | 68,417 |
Significant Accounting Policies Schedule Of Research And Development Costs 19 | 42,604 |
Significant Accounting Policies Schedule Of Research And Development Costs 20 | 88,684 |
Significant Accounting Policies Schedule Of Research And Development Costs 21 | 8,579 |
Significant Accounting Policies Schedule Of Research And Development Costs 22 | 6,907 |
Significant Accounting Policies Schedule Of Research And Development Costs 23 | 19,535 |
Significant Accounting Policies Schedule Of Research And Development Costs 24 | 17,912 |
Significant Accounting Policies Schedule Of Research And Development Costs 25 | 47,747 |
Significant Accounting Policies Schedule Of Research And Development Costs 26 | 77,679 |
Significant Accounting Policies Schedule Of Research And Development Costs 27 | 89,392 |
Significant Accounting Policies Schedule Of Research And Development Costs 28 | 150,406 |
Significant Accounting Policies Schedule Of Research And Development Costs 29 | 6,779 |
Significant Accounting Policies Schedule Of Research And Development Costs 30 | 0 |
Significant Accounting Policies Schedule Of Research And Development Costs 31 | 6,779 |
Significant Accounting Policies Schedule Of Research And Development Costs 32 | 0 |
Significant Accounting Policies Schedule Of Research And Development Costs 33 | 365,899 |
Significant Accounting Policies Schedule Of Research And Development Costs 34 | 398,410 |
Significant Accounting Policies Schedule Of Research And Development Costs 35 | 609,880 |
Significant Accounting Policies Schedule Of Research And Development Costs 36 | $ 673,881 |
Schedule of Properties Estimate
Schedule of Properties Estimated Useful life (Details) | 6 Months Ended |
Jun. 30, 2017USD ($) | |
Significant Accounting Policies Schedule Of Properties Estimated Useful Life [table Text Block] 1 | $ 15 |
Significant Accounting Policies Schedule Of Properties Estimated Useful Life [table Text Block] 2 | 3 |
Significant Accounting Policies Schedule Of Properties Estimated Useful Life [table Text Block] 3 | 4 |
Significant Accounting Policies Schedule Of Properties Estimated Useful Life [table Text Block] 4 | 3 |
Significant Accounting Policies Schedule Of Properties Estimated Useful Life [table Text Block] 5 | $ 15 |
Schedule of Property, Plant and
Schedule of Property, Plant and Equipment (Details) | 6 Months Ended |
Jun. 30, 2017USD ($) | |
Fixed Assets Schedule Of Property, Plant And Equipment 1 | $ 3,496 |
Fixed Assets Schedule Of Property, Plant And Equipment 2 | 26,489 |
Fixed Assets Schedule Of Property, Plant And Equipment 3 | 44,432 |
Fixed Assets Schedule Of Property, Plant And Equipment 4 | 74,417 |
Fixed Assets Schedule Of Property, Plant And Equipment 5 | 357 |
Fixed Assets Schedule Of Property, Plant And Equipment 6 | 2,697 |
Fixed Assets Schedule Of Property, Plant And Equipment 7 | 4,523 |
Fixed Assets Schedule Of Property, Plant And Equipment 8 | 7,577 |
Fixed Assets Schedule Of Property, Plant And Equipment 9 | 3,853 |
Fixed Assets Schedule Of Property, Plant And Equipment 10 | 29,186 |
Fixed Assets Schedule Of Property, Plant And Equipment 11 | 48,955 |
Fixed Assets Schedule Of Property, Plant And Equipment 12 | 81,994 |
Fixed Assets Schedule Of Property, Plant And Equipment 13 | 404 |
Fixed Assets Schedule Of Property, Plant And Equipment 14 | 10,645 |
Fixed Assets Schedule Of Property, Plant And Equipment 15 | 7,924 |
Fixed Assets Schedule Of Property, Plant And Equipment 16 | 18,973 |
Fixed Assets Schedule Of Property, Plant And Equipment 17 | 207 |
Fixed Assets Schedule Of Property, Plant And Equipment 18 | 3,818 |
Fixed Assets Schedule Of Property, Plant And Equipment 19 | 2,890 |
Fixed Assets Schedule Of Property, Plant And Equipment 20 | 6,915 |
Fixed Assets Schedule Of Property, Plant And Equipment 21 | 52 |
Fixed Assets Schedule Of Property, Plant And Equipment 22 | 1,276 |
Fixed Assets Schedule Of Property, Plant And Equipment 23 | 950 |
Fixed Assets Schedule Of Property, Plant And Equipment 24 | 2,278 |
Fixed Assets Schedule Of Property, Plant And Equipment 25 | 663 |
Fixed Assets Schedule Of Property, Plant And Equipment 26 | 15,739 |
Fixed Assets Schedule Of Property, Plant And Equipment 27 | 11,764 |
Fixed Assets Schedule Of Property, Plant And Equipment 28 | 28,166 |
Fixed Assets Schedule Of Property, Plant And Equipment 29 | 3,092 |
Fixed Assets Schedule Of Property, Plant And Equipment 30 | 15,844 |
Fixed Assets Schedule Of Property, Plant And Equipment 31 | 36,508 |
Fixed Assets Schedule Of Property, Plant And Equipment 32 | 55,444 |
Fixed Assets Schedule Of Property, Plant And Equipment 33 | 3,190 |
Fixed Assets Schedule Of Property, Plant And Equipment 34 | 13,447 |
Fixed Assets Schedule Of Property, Plant And Equipment 35 | 37,191 |
Fixed Assets Schedule Of Property, Plant And Equipment 36 | $ 53,828 |
Schedule of Convertible Debt (D
Schedule of Convertible Debt (Details) | 6 Months Ended |
Jun. 30, 2017USD ($) | |
Convertible Debentures Schedule Of Convertible Debt 1 | $ 1,213,397 |
Convertible Debentures Schedule Of Convertible Debt 2 | 0 |
Convertible Debentures Schedule Of Convertible Debt 3 | 1,213,397 |
Convertible Debentures Schedule Of Convertible Debt 4 | (852,418) |
Convertible Debentures Schedule Of Convertible Debt 5 | 0 |
Convertible Debentures Schedule Of Convertible Debt 6 | (852,418) |
Convertible Debentures Schedule Of Convertible Debt 7 | 360,979 |
Convertible Debentures Schedule Of Convertible Debt 8 | 0 |
Convertible Debentures Schedule Of Convertible Debt 9 | 360,979 |
Convertible Debentures Schedule Of Convertible Debt 10 | 368,496 |
Convertible Debentures Schedule Of Convertible Debt 11 | 140,182 |
Convertible Debentures Schedule Of Convertible Debt 12 | 508,678 |
Convertible Debentures Schedule Of Convertible Debt 13 | 729,475 |
Convertible Debentures Schedule Of Convertible Debt 14 | 64,098 |
Convertible Debentures Schedule Of Convertible Debt 15 | $ 869,657 |
Schedule of Stockholders' Equit
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details) | 6 Months Ended |
Jun. 30, 2017USD ($) | |
Equity Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1 | $ 0 |
Equity Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 2 | 0 |
Equity Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 3 | $ 1,693,750 |
Equity Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 4 | 0.20 |
Equity Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 5 | $ 1,693,750 |
Equity Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 6 | 0.20 |
Schedule of Stockholders' Equ36
Schedule of Stockholders' Equity Note, Warrants or Rights (Details) | 6 Months Ended |
Jun. 30, 2017USD ($) | |
Equity Schedule Of Stockholders' Equity Note, Warrants Or Rights 1 | $ 1,693,750 |
Equity Schedule Of Stockholders' Equity Note, Warrants Or Rights 2 | $ 0.20 |
Schedule of Share-based Payment
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions (Details) | 6 Months Ended |
Jun. 30, 2017USD ($) | |
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 1 | 0.9 |
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 2 | 8.8 |
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 3 | $ 3 |
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 4 | $ 10 |
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 5 | 1.01 |
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 6 | 2.31% |
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 7 | 0.73 |
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 8 | 2.45% |
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 9 | 67.24 |
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 10 | 106.88% |
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 11 | 65.99 |
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 12 | 99.04% |
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 13 | 0.00% |
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 14 | 0.00% |
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 15 | 0.00% |
Equity Schedule Of Share-based Payment Award, Stock Options, Valuation Assumptions 16 | 0.00% |
Schedule of Share-based Compens
Schedule of Share-based Compensation, Stock Options, Activity (Details) | 6 Months Ended |
Jun. 30, 2017USD ($) | |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 1 | $ 14,237,075 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 2 | 0.01 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 3 | $ (481,179) |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 4 | 0.01 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 5 | $ (100,000) |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 6 | 0.01 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 7 | $ 150,000 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 8 | 0.20 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 9 | $ 1,610,000 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 10 | 0.20 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 11 | $ 120,000 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 12 | 0.20 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 13 | $ 150,000 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 14 | 0.20 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 15 | $ 50,000 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 16 | 0.20 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 17 | $ 125,000 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 18 | 0.20 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 19 | $ 100,000 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 20 | 0.20 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 21 | $ 15,960,896 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 22 | 0.04 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 23 | $ 50,000 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 24 | 0.20 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 25 | $ 75,000 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 26 | 0.20 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 27 | $ 150,000 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 28 | 0.20 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 29 | $ 800,000 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 30 | 0.20 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 31 | $ (50,000) |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 32 | 0.01 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 33 | $ 360,000 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 34 | 0.20 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 35 | $ 17,345,896 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 36 | 0.05 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 37 | $ 875,000 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 38 | 0.20 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 39 | $ 18,220,896 |
Equity Schedule Of Share-based Compensation, Stock Options, Activity 40 | 0.06 |
Schedule of Disclosure of Share
Schedule of Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2017USD ($) | Dec. 31, 2016USD ($) | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 1 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 2 | $ 9,750,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 3 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 4 | 5.18 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 5 | $ 9,750,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 6 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 7 | 5.18 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 8 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 9 | $ 481,179 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 10 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 11 | 0.91 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 12 | $ 481,179 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 13 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 14 | 0.91 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 15 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 16 | $ 800,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 17 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 18 | 1.15 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 19 | $ 680,001 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 20 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 21 | 1.15 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 22 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 23 | $ 1,924,717 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 24 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 25 | 3.37 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 26 | $ 1,924,717 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 27 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 28 | 3.37 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 29 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 30 | $ 500,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 31 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 32 | 1.51 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 33 | $ 500,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 34 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 35 | 1.51 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 36 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 37 | $ 150,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 38 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 39 | 3.85 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 40 | $ 150,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 41 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 42 | 3.85 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 43 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 44 | $ 150,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 45 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 46 | 2.82 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 47 | $ 150,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 48 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 49 | 2.82 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 50 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 51 | $ 120,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 52 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 53 | 5.16 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 54 | $ 40,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 55 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 56 | 5.16 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 57 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 58 | $ 1,610,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 59 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 60 | 5.11 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 61 | $ 536,667 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 62 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 63 | 5.11 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 64 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 65 | $ 150,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 66 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 67 | 5.18 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 68 | $ 100,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 69 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 70 | 5.18 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 71 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 72 | $ 50,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 73 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 74 | 5.40 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 75 | $ 16,667 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 76 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 77 | 5.40 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 78 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 79 | $ 125,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 80 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 81 | 5.42 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 82 | $ 41,667 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 83 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 84 | 5.42 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 85 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 86 | $ 100,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 87 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 88 | 5.44 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 89 | $ 33,333 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 90 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 91 | 5.44 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 92 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 93 | $ 50,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 94 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 95 | 5.63 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 96 | $ 16,667 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 97 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 98 | 5.63 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 99 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 100 | $ 75,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 101 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 102 | 5.69 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 103 | $ 25,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 104 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 105 | 5.69 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 106 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 107 | $ 150,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 108 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 109 | 8.85 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 110 | $ 70,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 111 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 112 | 8.85 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 113 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 114 | $ 800,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 115 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 116 | 3.94 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 117 | $ 173,334 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 118 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 119 | 3.94 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 120 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 121 | $ 360,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 122 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 123 | 6.34 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 124 | $ 180,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 125 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 126 | 6.34 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 127 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 128 | $ 875,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 129 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 130 | 6.92 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 131 | $ 0 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 132 | 0 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 133 | 0 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 134 | $ 18,220,896 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 135 | 0.06 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 136 | 4.64 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 137 | $ 14,869,232 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 138 | 0.03 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 139 | 4.47 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 1 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 2 | $ 9,750,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 3 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 4 | 5.67 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 5 | $ 9,750,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 6 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 7 | 5.67 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 8 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 9 | $ 481,179 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 10 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 11 | 1.41 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 12 | $ 240,589 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 13 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 14 | 1.41 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 15 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 16 | $ 800,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 17 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 18 | 1.64 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 19 | $ 680,001 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 20 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 21 | 1.64 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 22 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 23 | $ 1,924,717 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 24 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 25 | 3.87 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 26 | $ 1,924,717 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 27 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 28 | 3.87 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 29 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 30 | $ 500,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 31 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 32 | 2 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 33 | $ 500,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 34 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 35 | 2 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 36 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 37 | $ 150,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 38 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 39 | 4.34 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 40 | $ 100,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 41 | 0.01 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 42 | 4.34 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 43 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 44 | $ 150,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 45 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 46 | 4.34 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 47 | $ 50,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 48 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 49 | 4.34 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 50 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 51 | $ 120,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 52 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 53 | 5.65 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 54 | $ 40,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 55 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 56 | 5.65 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 57 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 58 | $ 1,610,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 59 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 60 | 5.60 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 61 | $ 536,667 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 62 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 63 | 5.60 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 64 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 65 | $ 150,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 66 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 67 | 5.67 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 68 | $ 100,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 69 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 70 | 5.67 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 71 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 72 | $ 50,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 73 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 74 | 5.90 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 75 | $ 16,667 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 76 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 77 | 5.90 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 78 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 79 | $ 125,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 80 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 81 | 5.92 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 82 | $ 41,667 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 83 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 84 | 5.92 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 85 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 86 | $ 100,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 87 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 88 | 5.93 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 89 | $ 33,333 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 90 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 91 | 5.93 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 92 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 93 | $ 50,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 94 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 95 | 6.13 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 96 | $ 0 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 97 | 0 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 98 | $ 0 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 99 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 100 | $ 75,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 101 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 102 | 6.18 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 103 | $ 0 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 104 | 0 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 105 | $ 0 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 106 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 107 | $ 150,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 108 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 109 | 9.35 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 110 | $ 30,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 111 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 112 | 9.35 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 113 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 114 | $ 800,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 115 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 116 | 4.43 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 117 | $ 26,667 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 118 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 119 | 4.43 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 120 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 121 | $ 360,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 122 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 123 | 6.84 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 124 | $ 180,000 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 125 | 0.20 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 126 | 6.84 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 127 | $ 17,345,896 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 128 | 0.05 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 129 | 5.03 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 130 | $ 14,250,308 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 131 | 0.02 | |
Equity Schedule Of Disclosure Of Share-based Compensation Arrangements By Share-based Payment Award 132 | 5.04 |
Consolidation, Less than Wholly
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net (Details) | 6 Months Ended |
Jun. 30, 2017USD ($) | |
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 1 | $ 13,209 |
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 2 | 2,454,192 |
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 3 | 183 |
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 4 | 310,977 |
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 5 | 13,392 |
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 6 | 2,765,169 |
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 7 | 730 |
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 8 | 1,241,171 |
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 9 | 203 |
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 10 | 345,198 |
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 11 | (313) |
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 12 | (532,084) |
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 13 | 14,012 |
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 14 | 3,819,454 |
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 15 | 1,051 |
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 16 | 1,786,656 |
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 17 | 15,063 |
Equity Consolidation, Less Than Wholly Owned Subsidiary, Parent Ownership Interest, Effects Of Changes, Net 18 | $ 5,606,110 |
Schedule of Future Minimum Rent
Schedule of Future Minimum Rental Payments for Operating Leases (Details) | 6 Months Ended |
Jun. 30, 2017USD ($) | |
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 1 | $ 312,272 |
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 2 | 37,824 |
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 3 | 350,096 |
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 4 | 0 |
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 5 | 22,064 |
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 6 | 22,064 |
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 7 | 312,272 |
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 8 | 59,888 |
Commitments And Guarantees Schedule Of Future Minimum Rental Payments For Operating Leases 9 | $ 372,160 |
Long-lived Assets by Geographic
Long-lived Assets by Geographic Areas (Details) - USD ($) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2017 | Dec. 31, 2016 | |
Geographic Information Long-lived Assets By Geographic Areas 1 | $ 0 | |
Geographic Information Long-lived Assets By Geographic Areas 2 | 53,828 | |
Geographic Information Long-lived Assets By Geographic Areas 3 | $ 53,828 | |
Geographic Information Long-lived Assets By Geographic Areas 1 | $ 0 | |
Geographic Information Long-lived Assets By Geographic Areas 2 | 55,444 | |
Geographic Information Long-lived Assets By Geographic Areas 3 | $ 55,444 |